Site map
Pages
- About Us
- Blog
- Contact form submit
- Contact us
- Cookie policy
- Corporate Governance
- CRO Services
- Datablocks test page
- Discovery, Development & Partnerships
- Events
- Front demo
- Gubra Green
- Gubra Resource Library
- GubraView: Transforming Data into Actionable Insights
- Home
- Investors Relations
- Latest news
- Newsletter signup
- Partnering Team
- Past events
- Privacy policy
- Resource Library
- RSS Aggregator
- Sitemap
- Whisleblower
- Whole brain c-Fos web store
Blog
- Understanding the blood-brain barrier: Function, structure, and role in CNS drug delivery
- AI-based lung histology in preclinical IPF models: Bridging preclinical and clinical insight
- AI-based scoring and quantitative image analysis in preclinical kidney disease models
- Quantifying neurodegenerative disease with 3D Imaging: A new standard in preclinical CNS research
- What is in vivo pharmacology?
- Liver histology in preclinical models: AI-powered analysis for translational research
- FDA approves semaglutide (Wegovy®) for MASH: What does this mean for drug development and preclinical innovation?
- Which IPF model offers the highest translational relevance in preclinical research?
- How to choose the right model for atherosclerosis studies
- The role of preclinical fibrosis models in advancing kidney disease research
- What does c-Fos really measure? Interpreting neuronal activation in research
- Closing the preclinical gap: How better research models can transform women’s health
- AI at Gubra: Enhancing research, innovation, and decision-making
- AI in drug discovery: Key trends shaping therapeutics in 2025
- How GubraView transforms data accessibility in preclinical research
- Best Preclinical Models for CKD, DKD, and Kidney Fibrosis
- How to utilize whole brain imaging in preclinical obesity studies
- What is a preclinical CRO?
- 5 Reasons to choose Gubra as a preclinical partner
- Understanding c-Fos and its applications in CNS research
- Breakthroughs in innovative peptide therapeutics
- Important checklist for selecting the right preclinical CRO: 32 questions to ask
- Anti-obesity drug development: Industry trends in 2024
- FDA approved Madrigal’s Resmetirom (Rezdiffra®) as first drug treatment for MASH. What now?
- GAN DIO-MASH model is top-ranked by the LITMUS consortium
For further information
Contact us
Gubra
Hørsholm Kongevej 11B
2970 Hørsholm
Denmark
+45 3152 2650